JP2007536224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007536224A5 JP2007536224A5 JP2007511366A JP2007511366A JP2007536224A5 JP 2007536224 A5 JP2007536224 A5 JP 2007536224A5 JP 2007511366 A JP2007511366 A JP 2007511366A JP 2007511366 A JP2007511366 A JP 2007511366A JP 2007536224 A5 JP2007536224 A5 JP 2007536224A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 239000011780 sodium chloride Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003107 substituted aryl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- -1 amino, amidino Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000030951 Phosphotransferases Human genes 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 200000000008 restenosis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56900904P | 2004-05-07 | 2004-05-07 | |
| PCT/US2005/010187 WO2005112932A2 (en) | 2004-05-07 | 2005-03-25 | Raf modulators and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009235794A Division JP2010006840A (ja) | 2004-05-07 | 2009-10-09 | Ｒａｆモジュレーターおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007536224A JP2007536224A (ja) | 2007-12-13 |
| JP2007536224A5 true JP2007536224A5 (US07476746-20090113-C00311.png) | 2009-08-27 |
| JP4604086B2 JP4604086B2 (ja) | 2010-12-22 |
Family
ID=35428836
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511366A Expired - Fee Related JP4604086B2 (ja) | 2004-05-07 | 2005-03-25 | Ｒａｆモジュレーターおよびその使用方法 |
| JP2009235794A Withdrawn JP2010006840A (ja) | 2004-05-07 | 2009-10-09 | Ｒａｆモジュレーターおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009235794A Withdrawn JP2010006840A (ja) | 2004-05-07 | 2009-10-09 | Ｒａｆモジュレーターおよびその使用方法 |
Country Status (6)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0419481D0 (en) * | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| EP2046292B1 (en) * | 2006-07-21 | 2010-03-03 | Novartis AG | Formulations for benzimidazolyl pyridyl ethers |
| CA2689514C (en) | 2007-06-05 | 2015-09-29 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JP5350247B2 (ja) | 2007-08-29 | 2013-11-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2010064611A1 (ja) | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| JP2012517448A (ja) * | 2009-02-11 | 2012-08-02 | リアクション バイオロジー コープ． | 選択的キナーゼ阻害剤 |
| WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
| US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
| ME02663B (me) | 2010-10-06 | 2017-06-20 | Glaxosmithkline Llc | Derivati benzimidazola kao inhibitori pi3 kinaze |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2014103947A1 (ja) * | 2012-12-25 | 2014-07-03 | 日本曹達株式会社 | ハロゲン化アニリンおよびその製造方法 |
| EP2842614A1 (en) * | 2013-08-30 | 2015-03-04 | Biotage AB | Sample preparation method for analysis of acrylamide |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| TWI742513B (zh) | 2013-11-18 | 2021-10-11 | 美商弗瑪治療公司 | 作為bet溴域抑制劑之四氫喹啉組成物 |
| WO2015164208A1 (en) * | 2014-04-23 | 2015-10-29 | Sun Chemical Corporation | Led photoinitiators |
| US10562886B2 (en) | 2015-05-21 | 2020-02-18 | The Regents Of The University Of California | Anti-cancer compounds |
| WO2017091681A1 (en) | 2015-11-24 | 2017-06-01 | Aclaris Therapeutics, Inc. | Selective kinase inhibitors |
| US11028055B2 (en) | 2015-11-30 | 2021-06-08 | Children's Medical Center Corporation | Compounds for treating proliferative diseases |
| AU2017280334C1 (en) | 2016-06-24 | 2022-10-20 | AtlasMedx, Inc | Phthalazine derivatives as inhibitors of PARP1, PARP2 and/or tubulin useful for the treatment of cancer |
| WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| AR114793A1 (es) | 2018-04-18 | 2020-10-14 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| HUE066335T2 (hu) | 2018-10-05 | 2024-07-28 | Annapurna Bio Inc | Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére |
| CR20220371A (es) | 2020-02-07 | 2022-10-27 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| EP4146639A1 (en) | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| JP2023533724A (ja) | 2020-07-02 | 2023-08-04 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物 |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| EP4267574A1 (en) | 2020-12-23 | 2023-11-01 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
| CN113045479B (zh) * | 2021-03-29 | 2022-05-24 | 南京工业大学 | 一种可见光促进3-羟基异吲哚-1-酮类化合物的合成方法 |
| TW202334139A (zh) | 2021-11-09 | 2023-09-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑 |
| WO2023178285A1 (en) | 2022-03-17 | 2023-09-21 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004015130A2 (en) * | 2002-08-07 | 2004-02-19 | Exelixis | Modulators of rabggt and methods of use thereof |
| WO2004103974A1 (ja) | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | 置換２－オキソキノリン化合物およびその医薬用途 |
-
2005
- 2005-03-25 WO PCT/US2005/010187 patent/WO2005112932A2/en active Application Filing
- 2005-03-25 JP JP2007511366A patent/JP4604086B2/ja not_active Expired - Fee Related
- 2005-03-25 AU AU2005244736A patent/AU2005244736B2/en not_active Ceased
- 2005-03-25 EP EP05731363A patent/EP1751124A4/en not_active Withdrawn
- 2005-03-25 CA CA2565200A patent/CA2565200C/en not_active Expired - Fee Related
- 2005-03-25 US US11/568,789 patent/US7846959B2/en active Active
-
2009
- 2009-10-09 JP JP2009235794A patent/JP2010006840A/ja not_active Withdrawn
-
2010
- 2010-10-12 US US12/903,031 patent/US8697737B2/en active Active
